HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.
Krzesaj. Patryck K PK; Seydafkan. Shabnam S; Miller. Anna I AI; Chen. Hui Ting HT; Premsrirut. Prem P; Shim. Alfred A; Mcglinchey. Steven S; Yazdi. Ehsan E; Brandt-Rauf. Paul P; Silberstein. Miriam M; Jahari. Gholamali G; Feinman. Richard D RD; Pincus. Matthew R MR
Key Findings
- PNC-27 kills cervical cancer (HTB-35/SiHa) cells at an IC50 of about 12.4 µM.
- Normal cervical cells (PCS-480) are not affected by the same doses of PNC-27.
- Cancer cells display HDM-2 on their membranes, which is the binding target for PNC-27; normal cells lack this membrane HDM-2.
Practical Outcomes
- For now, PNC-27 is a laboratory tool, not a ready‑to‑use supplement or drug. The findings suggest a possible new way to target cancers that show membrane HDM-2, but anyone interested should wait for clinical trials and safety data before considering any self‑experimentation.
Summary
The peptide PNC-27 can kill cervical cancer cells while leaving normal cervical cells unharmed. It does this by attaching to a protein called HDM-2 that sits on the surface of cancer cells but not on healthy cells. The study shows the peptide works at low micromolar concentrations in lab dishes, but it’s still far from being a usable treatment for people.
Abstract
The peptide PNC-27 has been found to kill many different endodermal solid tissue and hematopoietic cancer cells but has no effect on normal cells. The mechanism involves binding to the HDM-2 protein, which is expressed in the membranes of cancer cells but not in normal (untransformed) cells. Our objectives in the current study are to determine 1) if PNC-27 is lethal to squamous cervical epithelial cancer cells but not to untransformed squamous cervical cells; 2) if membrane-bound HDM-2 is expressed uniquely in cervical cancer cells; and 3) whether HDM-2 is stable for detection in different types of preservative solutions. We determined dose response curves for incubation of PNC-27 with the human squamous cervical cancer cell line HTB-35 (also called SiHa cells) and with the untransformed human squamous cervical cell line, PCS-480. Cell viability was determined using the MTT and LDH release assays. Finally, slot blots and flow cytometry were used to determine membrane expression of HDM-2 using a polyclonal anti-HDM-2 antibody. We found that PNC-27 is cytotoxic even at low doses (IC<sub>50</sub>=12.4 μM) to the human HTB-35 cervical cancer squamous epithelial cell line but not to a counterpart normal human PCS-480 cell line. We found that HTB-35 cells express high levels of HDM-2 proteins in their membranes both in cell culture and in alcoholic preservative solutions but that the normal PCS-480 cells do not. Consistent with previous results, the data suggest that cervical cancer cells express HDM-2 in their membranes and that this is the target for PNC-27. PNC-27 kills cervical squamous cancer but not normal cervical cells due to the unique expression of HDM-2 in the cervical squamous cell membranes. Thus, PNC-27 may be an effective drug against this cancer. Our results further suggest that the expression of membrane-bound HDM-2 on cervical cancer cells is stable both in cell culture media and in alcoholic preservative fluid.
Study Information
pubmed
2025